Clinical Trials
7
Active:0
Completed:5
Trial Phases
2 Phases
Phase 1:5
Phase 2:2
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)β’ Click on a phase to view related trials
Phase 1
5 (71.4%)Phase 2
2 (28.6%)TRIO Bladder: A Study of Durvalumab Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation in Muscle-Invasive Bladder Cancer
Phase 1
Withdrawn
- Conditions
- Bladder Cancer
- Interventions
- First Posted Date
- 2019-08-29
- Last Posted Date
- 2020-07-07
- Lead Sponsor
- Daniel George, MD
- Registration Number
- NCT04073160
- Locations
- πΊπΈ
Duke University Medical Center, Durham, North Carolina, United States
Apalutamide and Abiraterone Acetate in African American and Caucasian Men With Metastatic Castrate Resistant Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Daniel George, MD
- Target Recruit Count
- 93
- Registration Number
- NCT03098836
- Locations
- πΊπΈ
Tulane University, New Orleans, Louisiana, United States
πΊπΈChesapeake Urology Associates, Baltimore, Maryland, United States
πΊπΈBarbara Ann Karmanos Cancer Institute, Detroit, Michigan, United States
A Phase Ib Study of Intravenous Copper Loading With Oral Disulfiram in Metastatic, Castration Resistant Prostate Cancer
Phase 1
Terminated
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2016-11-15
- Last Posted Date
- 2021-09-16
- Lead Sponsor
- Daniel George, MD
- Target Recruit Count
- 9
- Registration Number
- NCT02963051
- Locations
- πΊπΈ
Duke University Medical Center, Durham, North Carolina, United States
Pazopanib, Docetaxel, Prednisone Prostate
Phase 1
Completed
- Conditions
- Prostate Cancer
- Interventions
- First Posted Date
- 2011-06-30
- Last Posted Date
- 2018-06-06
- Lead Sponsor
- Daniel George, MD
- Target Recruit Count
- 36
- Registration Number
- NCT01385228
- Locations
- πΊπΈ
The University of Chicago, Chicago, Illinois, United States
πΊπΈDuke Cancer Institute, Durham, North Carolina, United States
A Phase Ib Study of Rad001 and Sutent to Treat Renal Cell Carcinoma
Phase 1
Completed
- Conditions
- Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2008-11-10
- Last Posted Date
- 2015-02-16
- Lead Sponsor
- Daniel George, MD
- Target Recruit Count
- 5
- Registration Number
- NCT00788060
- Locations
- πΊπΈ
Duke University Medical Center, Durham, North Carolina, United States
- Prev
- 1
- 2
- Next
News
No news found